Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Apr 23

PMID 35454025

Authors

Liang Lu

Xueyan Wan

Yu Xu

Juan Chen

Kai Shu

Ting Lei

Affiliations

Soon will be listed here.

Abstract

Pituitary adenomas (PAs) are benign lesions; nonetheless, some PAs exhibit aggressive behaviors, which lead to recurrence. The impact of pituitary dysfunction, invasion-related risks, and other complications considerably affect the quality of life of patients with recurrent PAs. Reliable prognostic factors are needed for recurrent PAs but require confirmation. This review summarizes research progress on two aspects-namely, the clinical and biological factors (biomarkers) for recurrent PAs. Postoperative residue, age, immunohistological subtypes, invasion, tumor size, hormone levels, and postoperative radiotherapy can predict the risk of recurrence in patients with PAs. Additionally, biomarkers such as Ki-67, p53, cadherin, pituitary tumor transforming gene, matrix metalloproteinase-9, epidermal growth factor receptor, fascin actin-bundling protein 1, cyclooxygenase-2, and some miRNAs and lncRNAs may be utilized as valuable tools for predicting PA recurrence. As no single marker can independently predict PA recurrence, we introduce an array of comprehensive models and grading methods, including multiple prognostic factors, to predict the prognosis of PAs, which have shown good effectiveness and would be beneficial for predicting PA recurrence.

Citing Articles

Radiological and Immunohistochemical Characteristics of PitNETs in 79 Patients Undergoing Neurosurgery.

Krzentowska A, Czepko R, Adamek D, Filipowicz M, Broniatowska E, Golkowski F Cancers (Basel). 2025; 17(4).

PMID: 40002261 PMC: 11852720. DOI: 10.3390/cancers17040666.

Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases.

Lisina D, Mazeeva V, Zakharova E, Sorokina A, Dzhemileva L, Grigoriev A BMC Endocr Disord. 2025; 25(1):37.

PMID: 39939927 PMC: 11816545. DOI: 10.1186/s12902-025-01865-9.

Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas.

Xu D, Wang L, Zheng M Immun Inflamm Dis. 2024; 12(12):e70098.

PMID: 39688352 PMC: 11650491. DOI: 10.1002/iid3.70098.

KLHL14 and E-Cadherin Nuclear Co-Expression as Predicting Factor of Nonfunctioning PitNET Invasiveness: Preliminary Study.

Berardinelli J, Russo V, Canciello A, Di Giacinto O, Mauro A, Nardinocchi D J Clin Med. 2024; 13(15).

PMID: 39124679 PMC: 11312959. DOI: 10.3390/jcm13154409.

Exosomal AFAP1-AS1 Promotes the Growth, Metastasis, and Glycolysis of Pituitary Adenoma by Inhibiting HuR Degradation.

Tang H, Zhu D, Li W, Zhang G, Zhang H, Peng Q Mol Neurobiol. 2024; 62(2):2212-2229.

PMID: 39090353 PMC: 11772456. DOI: 10.1007/s12035-024-04387-y.

References

Kontogeorgos G . Update on pituitary adenomas in the 2017 World Health Organization classification: innovations and perspectives. Hormones (Athens). 2021; 20(2):287-291. DOI: 10.1007/s42000-020-00269-9. View

Ozgen T, Oruckaptan H, Ozcan O, Acikgoz B . Prolactin secreting pituitary adenomas: analysis of 429 surgically treated patients, effect of adjuvant treatment modalities and review of the literature. Acta Neurochir (Wien). 2000; 141(12):1287-94. DOI: 10.1007/s007010050432. View

Sonino N, Zielezny M, Fava G, Fallo F, Boscaro M . Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab. 1996; 81(7):2647-52. DOI: 10.1210/jcem.81.7.8675592. View

Zheng X, Li S, Zhang W, Zang Z, Hu J, Yang H . Current biomarkers of invasive sporadic pituitary adenomas. Ann Endocrinol (Paris). 2016; 77(6):658-667. DOI: 10.1016/j.ando.2016.02.004. View

Hofstetter C, Nanaszko M, Mubita L, Tsiouris J, Anand V, Schwartz T . Volumetric classification of pituitary macroadenomas predicts outcome and morbidity following endoscopic endonasal transsphenoidal surgery. Pituitary. 2011; 15(3):450-63. DOI: 10.1007/s11102-011-0350-z. View

Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T . Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol. 2016; 175(1):63-72. DOI: 10.1530/EJE-16-0206. View

Cardinal T, Zada G, Carmichael J . The role of reoperation after recurrence of Cushing's disease. Best Pract Res Clin Endocrinol Metab. 2021; 35(2):101489. DOI: 10.1016/j.beem.2021.101489. View

Heringer L, Machado de Lima M, Rotta J, Botelho R . Effect of Stereotactic Radiosurgery on Residual or Relapsed Pituitary Adenoma: A Systematic Review and Meta-Analysis. World Neurosurg. 2020; 136:374-381.e4. DOI: 10.1016/j.wneu.2019.11.041. View

Zhu H, Guo J, Shen Y, Dong W, Gao H, Miao Y . Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas. Clin Cancer Res. 2018; 24(22):5757-5766. DOI: 10.1158/1078-0432.CCR-18-0472. View

10.

Lyu W, Fei X, Chen C, Tang Y . Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma. Gland Surg. 2021; 10(2):807-815. PMC: 7944052. DOI: 10.21037/gs-21-47. View

11.

Zhou K, Jin H, Luo Y . Expression and significance of E-cadherin and β-catenins in pituitary adenoma. Int J Surg Pathol. 2013; 21(4):363-7. DOI: 10.1177/1066896912471850. View

12.

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

13.

Gruppetta M, Formosa R, Falzon S, Ariff Scicluna S, Falzon E, Degeatano J . Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas. Pituitary. 2017; 20(3):358-371. DOI: 10.1007/s11102-017-0803-0. View

14.

Andrews J, Joshi R, Pereira M, Oh T, Haddad A, Pereira K . Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series. World Neurosurg. 2021; 151:e185-e191. PMC: 9466646. DOI: 10.1016/j.wneu.2021.04.003. View

15.

Chang E, Zada G, Kim S, Lamborn K, Quinones-Hinojosa A, Tyrrell J . Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg. 2008; 108(4):736-45. DOI: 10.3171/JNS/2008/108/4/0736. View

16.

Liu C, Gao H, Cao L, Gui S, Liu Q, Li C . The role of FSCN1 in migration and invasion of pituitary adenomas. Mol Cell Endocrinol. 2015; 419:217-24. DOI: 10.1016/j.mce.2015.10.021. View

17.

Pala A, Knoll A, Schneider M, Etzrodt-Walter G, Karpel-Massler G, Wirtz C . The Benefit of Intraoperative Magnetic Resonance Imaging in Endoscopic and Microscopic Transsphenoidal Resection of Recurrent Pituitary Adenomas. Curr Oncol. 2022; 29(1):392-401. PMC: 8774543. DOI: 10.3390/curroncol29010035. View

18.

Omar 2nd A, Munoz D, Goguen J, Lee J, Rotondo F, Kovacs K . Resection of the medial wall of the cavernous sinus in functioning pituitary adenomas: Technical note and outcomes in a matched-cohort study. Clin Neurol Neurosurg. 2021; :106306. DOI: 10.1016/j.clineuro.2020.106306. View

19.

Saeger W, Koch A . Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors. Exp Clin Endocrinol Diabetes. 2021; 129(3):146-156. DOI: 10.1055/a-1310-7900. View

20.

Ferreira J, de Mello P, Magalhaes A, Botelho C, Naves L, Nose V . [Non-functioning pituitary adenomas: clinical features and immunohistochemistry]. Arq Neuropsiquiatr. 2006; 63(4):1070-8. DOI: 10.1590/s0004-282x2005000600029. View